Evidence map›Paper›PMID 37091227›Full record

ArticleiScience2023

Semi-supervised analysis of myeloid and T cell behavior in

Florian Laforêts, Panoraia Kotantaki, Beatrice Malacrida, Samar Elorbany, Ranjit Manchanda, Emmanuel Donnadieu, Frances Balkwill

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Florian LaforêtsBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, EC1M6BQ London, UK.
Panoraia KotantakiBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, EC1M6BQ London, UK.
Beatrice MalacridaBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, EC1M6BQ London, UK.
Samar ElorbanyBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, EC1M6BQ London, UK.
Ranjit ManchandaWolfson Institute of Population Health, CRUK Barts Cancer Centre, Queen Mary University of London, EC1M 6BQ London, UK.
Emmanuel DonnadieuUniversité Paris Cité, CNRS, INSERM, Equipe Labellisée Ligue Contre le Cancer, Institut Cochin, 75014 Paris, France.
Frances BalkwillBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, EC1M6BQ London, UK.
Queen Mary University of London · GBCentre National de la Recherche Scientifique · FR

Funding

Cancer Research UK 25714Cancer Research UK A16354
6 · The paper itself

Abstract

Studies of the high-grade serous ovarian cancer (HGSOC) tumor microenvironment, the most lethal gynecological cancer, aim to enhance the efficiency of established therapies. Cell motility is an important process of anti-tumor response. Using

Indexed as

CancerImmunologyMicroenvironment

Identifiers

PMID37091227
PMCPMC10119804
OpenAlexW4361283743

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.